Access to this full-text is provided by PLOS.
Content available from PLOS Genetics
This content is subject to copyright.
PLOS Genetics | https://doi.org/10.1371/journal.pgen.1011622 March 18, 2025 1 / 29
OPEN ACCESS
Citation: Chen L, Yang H, Wang J, Zhang H,
Fu K, Yan Y, et al. (2025) MEOX1-mediated
transcriptional regulation of circABHD3
exacerbates hepatic fibrosis through promoting
m6A/YTHDF2-dependent YPEL3 mRNA decay
to activate β-catenin signaling. PLoS Genet
21(3): e1011622. https://doi.org/10.1371/
journal.pgen.1011622
Editor: Anna Babour, Institut Jacques Monod,
FRANCE
Received: August 15, 2024
Accepted: February 13, 2025
Published: March 18, 2025
Copyright: © 2025 Chen et al. This is an open
access article distributed under the terms of
the Creative Commons Attribution License,
which permits unrestricted use, distribution,
and reproduction in any medium, provided the
original author and source are credited.
Data availability statement: The authors
confirm that all data underlying the findings are
fully available without restriction. All relevant
data are within the paper and its Supporting
Information files.
Funding: This study was funded by grants
from the National Natural Science Foundation
RESEARCH ARTICLE
MEOX1-mediated transcriptional regulation
of circABHD3 exacerbates hepatic fibrosis
through promoting m6A/YTHDF2-dependent
YPEL3 mRNA decay to activate β-catenin
signaling
Limin Chen1, Hui Yang1, Juan Wang1, Haoye Zhang1, Kangkang Fu1, Yu Yan1,
Zhenguo Liu 1,2*
1 Department of Infectious Disease, The Third Xiangya Hospital, Central South University, Changsha,
Hunan Province, P.R. China, 2 Hunan Key Laboratory of Viral Hepatitis, Xiangya Hospital, Central South
University, Changsha, Hunan Province, P.R. China
* liuzg729@163.com
Abstract
Background
Hepatic brosis may progress to liver cirrhosis and eventually cause death. Epithelial-
mesenchymal transition (EMT) of hepatocytes plays critical roles in hepatic brosis.
Exploring the mechanisms underlying EMT is crucial for a better understanding of hepatic
brosis pathogenesis.
Methods
Hepatocyte EMT wad induced with TGF-β1 and evaluated by Western blotting and immu-
nouorescence staining. Methylated RNA immunoprecipitation (MeRIP) was applied to
assess N6-methyladenosine (m6A) modication. RIP and RNA pull-down assays were
performed to analyze the interaction between circABHD3, YTHDF2 and YPEL3 mRNA.
MEOX1-mediated transcription of ABHD3 was examined by luciferase and chromatin
immunoprecipitation (ChIP). Mice were intraperitoneally injected with CCl4 or treated with
bile duct ligation (BDL) surgery for hepatic brosis induction. Liver injury and collagen
deposition were examined with hematoxylin and eosin (HE), Masson, and Sirius Red
staining. Alanine transaminase (ALT), aspartate transaminase (AST) and hydroxyproline
(HYP) were examined using ELISA.
Results
CircABHD3 was upregulated in in vitro and in vivo models of hepatic brosis and patients.
Knockdown of circABHD3 inhibited TGF-β1-induced expression of brosis markers, EMT
and mitochondrial impairment in hepatocytes. MEOX1 could directly bind to the pro-
moter of ABHD3 to facilitate its transcription and subsequent circABHD3 generation.
Knockdown of MEOX1 suppressed TGF-β1-induced EMT and mitochondrial impairment
PLOS Genetics | https://doi.org/10.1371/journal.pgen.1011622 March 18, 2025 2 / 29
PLOS GeneticS CircABHD3 exacerbates hepatic brosis via YPEL3-mediated β-catenin signaling
through suppression of circABHD3. CircABHD3 destabilized YPEL3 mRNA via promoting
YTHDF2-dependent recognition of m6A-modied YPEL3 mRNA to trigger β-catenin signaling
activation. Furthermore, circABHD3 silencing-mediated inhibition of EMT and mitochondrial
impairment was counteracted by YPEL3 knockdown and activation of β-catenin signaling.
Depletion of circABHD3 signicantly reduced EMT, mitochondrial impairment and hepatic
brosis via promoting YPEL3 expression and suppressing β-catenin signaling in vivo.
Conclusion
MEOX1-mediated generation of circABHD3 promotes EMT and mitochondrial impairment
by enhancing YTHDF2-mediated degradation of YPEL3 mRNA and activating downstream
β-catenin signaling, thus exacerbating hepatic brosis.
Author summary
Hepatic fibrosis is a pathological condition characterized by the excessive deposition
of extracellular matrix (ECM) proteins within the liver that leads to liver dysfunction.
Epithelial-mesenchymal transition (EMT) is proposed to contribute to fibrogenesis
by enabling epithelial cells to acquire a fibroblastic phenotype and participate in the
production of ECM components. Understanding the cellular and molecular mechanisms
involved in hepatic fibrosis is crucial for the development of effective therapies to prevent
or reverse this condition and its associated complications. Here, we describe a novel
mechanism involving circular RNA and EMT in liver fibrosis. CircABHD3 promotes
EMT and mitochondrial impairment via facilitating YTHDF2-mediated degradation of
YPEL3 mRNA and activating downstream β-catenin signaling, thus exacerbating hepatic
fibrosis. This finding is particularly important as it provides a novel insight into the
pathogenesis of hepatic fibrosis and potential targets for anti-fibrosis treatment.
Introduction
Hepatic fibrosis is characterized by excessive formation of extracellular matrix (ECM) pro-
teins such as collagen and caused by many chronic liver conditions [1]. The major causes of
hepatic fibrosis include fatty liver disorder, excessive drinking, autoimmune hepatitis and
chronic hepatitis B or C virus infection. Hepatic fibrosis usually shows no or vague symptoms,
which may cause delayed medical treatment for patients. Unfortunately, hepatic fibrosis can
progress to a fatal liver cirrhosis, and liver transplantation may be the only option for many
patients. Currently, the treatment for hepatic fibrosis primarily focuses on removing the cause
of fibrosis such as anti-hepatitis virus and limiting alcohol consumption, anti-inflammation
and liver protection [2]. Exploring the mechanisms underlying the pathogenesis of hepatic
fibrosis is central for developing promising therapies.
Epithelial-mesenchymal transition (EMT), a process by which epithelial cells acquire prop-
erties of mesenchymal cells and lose intercellular adhesion and cell polarity [3], may be a key
process in hepatic fibrosis. Various cells in the liver, such as bile duct cells and hepatocytes,
can be differentiated into myofibroblasts via EMT [4]. Myofibroblasts are major ECM-
generating cells, thereby contributing to the formation of liver fibrosis [5]. Transforming
growth factor-β1 (TGF-β1) is a key regulator that activates the differentiation of liver stellate
cells into myofibroblasts, resulting in fibrosis [6]. Inhibition of TGF-β1-mediated EMT in
of China (No. 82170639 to ZL), the National
Natural Science Foundation of China Youth
Fund (No. 82200671 to JW), and the Hunan
Provincial Natural Science Foundation
(2021JJ30997 to LC, 2022JJ70068 to ZL).
The funders had no role in study design, data
collection and analysis, decision to publish, or
preparation of the manuscript.
Competing interests: The authors have
declared that no competing interests exist.
PLOS Genetics | https://doi.org/10.1371/journal.pgen.1011622 March 18, 2025 3 / 29
PLOS GeneticS CircABHD3 exacerbates hepatic brosis via YPEL3-mediated β-catenin signaling
liver cells improves hepatic fibrosis [7,8]. Further investigations of the regulation of EMT are
essential for a better understanding of the pathogenesis of hepatic fibrosis.
Wnt/β-catenin signaling is one of the most important pathways involved in the regulation
of EMT [9,10]. Wnt/β-catenin also regulate the vimentin, collagen 1, and fibronectin in liver
fibrosis [11]. In fibrosis, the Wnt signaling is active, the β-catenin/E-cadherin complex is
disrupted, β-catenin translocates into the nucleus, and E-cadherin is degraded thus enhanc-
ing the loss of the epithelial phenotype [12]. Ge et al. reported that β-catenin was highly
expressed in liver fibrosis [13]. Therefore, understanding the mechanisms underlying the
regulation of β-catenin signaling in hepatic fibrosis is important. Glycogen synthase kinase
3β (GSK-3β), an evolutionarily conserved serine/threonine kinase, phosphorylates β-catenin
at Ser33, Ser37 and Thr41 to promote its degradation, thus downregulating downstream
EMT-related markers and inhibiting EMT [14,15]. Liu et al. observed that bone marrow mes-
enchymal stem cells (BMSCs) suppressed hepatic fibrosis through activation of GSK-3β and
subsequent inhibition of β-catenin signaling [16]. Also, Yippee-like-3 (YPEL3) is emerging
as a negative regulator of β-catenin signaling. Zhang et al. found that YPEL3 inhibited EMT
and metastasis in nasopharyngeal carcinoma via suppressing β-catenin signaling [17]. YPEL3
inhibits β-catenin signaling to negatively regulate endometrial function [18]. The suppressive
role of YPEL3 in β-catenin signaling indicates that YPEL3 may be involved in hepatic fibro-
sis. N6-methyladenosine (m6A) modification is an important posttranslational modification
that controls RNA stability and fate [19]. We found through bioinformatics analysis that
there was an m6A modification site on YPEL3 mRNA. However, m6A-mediated regulation
of YPEL3 mRNA stability is unknown.
Circular RNAs, a novel class of non-coding RNAs with a closed loop, show important
activity in hepatic fibrosis. Zhou et al. reported 69 differentially expressed circRNAs in hepatic
fibrosis [20], suggesting that circRNAs may be regulators of hepatic fibrosis. For example,
circFBXW4 and circPSD3 ameliorate liver fibrosis through various mechanisms [21,22].
Circular RNA α/β-hydrolase domain-containing 3 (circABHD3, hsa_circ_0047086) is signifi-
cantly upregulated in hepatic fibrosis tissues, but its roles in EMT and hepatic fibrosis remain
largely unknown. Besides, the upstream regulatory mechanism of circABHD3 generation
also remains unclear. We identified two potential binding sites for Mesenchyme Homeobox 1
(MEOX1) in the promoter region of ABHD3, indicating the possibility that MEOX1 may be
implicated in the regulation of ABHD3 transcription and circABHD3 generation.
In our study, we reported that MEOX1 bound to the promoter of ABHD3 to enhance circABHD3
generation. Subsequently, circABHD3 promoted YTHDF2-dependent recognition of YPEL3 mRNA
to destabilize YPEL3 mRNA to reduce its expression and activate β-catenin signaling, thus exacerbat-
ing hepatic fibrosis. Our study sheds novel light on the pathogenesis of hepatic fibrosis and provides
potential therapeutic targets such as circABHD3, YPEL3 and β-catenin signaling.
Methods
Ethics approval and consent to participate
Written informed consent was provided by patients and volunteers, and our study was
approved by the Ethics Committee of the Third Xiangya Hospital, Central South University.
Animal procedures were approved by the Animal Care and Use Committee of the Third
Xiangya Hospital, Central South University (the approval number: 2021-S278).
Clinical specimens
Liver biopsy samples were collected from eight patients with hepatic fibrosis at the Third
Xiangya Hospital, Central South University and stored at -80°C for RNA extraction. All
PLOS Genetics | https://doi.org/10.1371/journal.pgen.1011622 March 18, 2025 4 / 29
PLOS GeneticS CircABHD3 exacerbates hepatic brosis via YPEL3-mediated β-catenin signaling
patients included in this study were ≥18-year-old and did not receive any treatment. Patients
with cancers, organ transplantation, pregnancy, drug and alcohol abuse and severe other
diseases are excluded. We also collected liver samples from eight transplant donors as con-
trols. Written informed consent was provided by patients and volunteers, and our study was
approved by the Ethics Committee of the Third Xiangya Hospital, Central South University
(the approval number: 2021-S278).
Cell culture and treatment
Human and murine liver cell lines THLE-2 and AML12 were obtained from the American
Type Culture Collection (Manassas, VA, USA) and maintained in Dulbecco’s Modified Eagle
Medium (DMEM, Gibco, Carlsbad, CA, USA) supplemented with 10% fetal bovine serum
(FBS, Gibco). To establish a cell model of hepatic fibrosis, cells were treated with TGF-β1
(PeproTech, Cranbury, NJ, USA) at 5 ng/mL for 48 h [23]. For inducing the activation of
β-catenin signaling, cells were treated with lithium chloride (LiCl) at 50 mM for 16 h [24].
Cell transfection
The sequences of circABHD3 and MEOX1 were inserted into the pLCDH-ciR vector (Gen-
eseed Biotech, Guangzhou, China) and pcDNA3.1 Mammalian Expression Vector (Thermo
Fisher Scientific, Waltham, MA, USA) for overexpression, respectively. YTHDF2 (shY-
THDF2), circABHD3 (shcircABHD3), YPEL3 (shYPEL3), MEOX1 (shMEOX1#1, #2 and #3)
and scramble shRNA (shNC) lentiviral constructs were provided by GenePharma (Shanghai,
China). THLE-2 and AML12 cells were transiently transfected with shNC, shcircABHD3,
shYTHDF2, shYPEL3, shMEOX1, circABHD3, MEOX1 or empty vector with Lipofectamine
2000 (Thermo Fisher Scientific). After 48 h, cells were detached and washed for subsequent
experiments.
Nuclear and cytoplasmic RNA extraction
Nuclear and cytoplasmic RNA of THLE-2 cells were extracted separately using Cytoplasmic
and Nuclear RNA Purification Kit (Norgen, Thorold, ON, Canada) and reversely transcribed
into cDNA. The abundance of glyceraldehyde-3-phosphate dehydrogenase (GAPDH), U6
snRNA, MATAL1, Mt-COI and circABHD3 was examined by qRT-PCR.
CircABHD3 characterization
Total RNA was extracted from THLE-2 cells and treated with RNase R (5 U/µg, Abcam, Cam-
bridge, UK) at 37°C for 1h. The remaining of circABHD3 and ABHD3 mRNA was analyzed
by qRT-PCR. THLE-2 cells were treated with actinomycin D (a transcription inhibitor, Sell-
eck, Shanghai, China) at 4 µg/mL for 0, 4, 8,16 and 24 h, and RNA was isolated and subjected
for quantitative reverse transcription PCR (qRT-PCR) analysis of circABHD3 and ABHD3
mRNA. Divergent primers were designed for amplifying circABHD3, and the junction site of
circABHD3 was identified by Sanger sequencing (Sangon, Shanghai, China).
Methylated RNA immunoprecipitation (MeRIP)
The m6A level of YPEL3 mRNA was analyzed using the Magna MeRIP m6A Kit (Millipore,
Billerica, MA, USA). Briefly, RNA was extracted from THLE-2 and AML12 cells and quan-
tified with the Nanodrop spectrophotometer. Magnetic beads/anti-m6A antibody complex
was prepared by adding 10 µg of the anti-m6A antibody into magnetic beads and incubating
for half an hour. During preparing the magnetic beads/antibody complex, RNA (200 µg) was
PLOS Genetics | https://doi.org/10.1371/journal.pgen.1011622 March 18, 2025 5 / 29
PLOS GeneticS CircABHD3 exacerbates hepatic brosis via YPEL3-mediated β-catenin signaling
fragmented to approximately 100 nt. MeRIP Reaction Mixture was prepared following the
manual, and the magnetic beads/antibody complex was mixed with MeRIP Reaction Mixture
thoroughly for 2 h of incubation. Subsequently, the sample was placed on the magnet and
washed twice. The immunoprecipitated m6A-modified RNAs were recovered and subjected
for qRT-PCR analysis of YPEL3 mRNA.
YPEL3 mRNA stability analysis
To analyze the stability of YPEL3 mRNA, after treatment, THLE-2 and AML12 cells were
treated with actinomycin D at 4 µg/mL for 0, 4, 8 or 12 h and resuspended in Trizol reagent
for RNA isolation. Subsequently, RNA was reversely transcribed, and the remaining of YPEL3
mRNA was detected by qRT-PCR and normalized to its remaining at 0 h.
Fluorescence in situ hybridization (FISH) and immunofluorescence (IF)
staining
Coverslip-bound cells were fixed in 3.7% paraformaldehyde solution for 10 min and immersed
in 0.5% Triton X-100 for 20 min. For IF staining, cells were blocked in 5% bovine serum
albumin (BSA) solution and incubated with primary antibodies against E-cadherin (1:1000,
mouse, ab231303, Abcam) and N-cadherin (1: 500, rabbit, ab18203, Abcam) overnight. Cells
were rinsed and incubated with Alexa Fluor 488- (1:2000, goat anti-mouse, Thermo Fisher
Scientific) and Alexa Fluor 647-conjugated (1:2000, goat anti-rabbit, Thermo Fisher Scien-
tific) secondary antibodies for 1 h. For combined FISH and IF staining, cells were treated with
proteinase K (Thermo Fisher Scientific) at 8 µg/µL for 30 min and pre-hybridized for 2 h.
Subsequently, cells were hybridized with Cy3-labelled circABHD3 probes (40 nM) at 56°C
overnight. After rinse, cells were blocked and incubated with a YTHDF2 antibody (1:500,
rabbit, Abcam) for 1 h in the dark. Cells were washed and incubated with Alexa Fluor 594-
conjugated secondary antibody (1:2000, goat anti-rabbit, Thermo Fisher Scientific) for 1 h.
Finally, cells were stained with 4’,6-diamidino-2-phenylindole (DAPI, Solarbio, Beijing,
China) and mounted for examination under a fluorescence microscope.
RNA immunoprecipitation (RIP)
Imprint RNAImmunoprecipitation (RIP) Kit (Sigma-Aldrich, Saint Louis, MO, USA) was used
for RIP assays according to the manual. In brief, cells were scraped, resuspended in lysis buffer
supplemented with protease and ribonuclease inhibitors and incubated for 20 min on ice fol-
lowed by supernatant collection. For RIP, a YTHDF2 antibody (10 µg, rabbit, ab220163, Abcam)
was pre-bound to protein A magnetic beads following the manual. Antibody-coated magnetic
beads were mixed with the supernatants in IP buffer and incubated with rotation at 4°C over-
night for immunoprecipitation of protein-RNA complexes. Magnetic beads were washed, and
RNA was purified and subjected to qRT-PCR analysis of circABHD3 and electrophoresis.
Dual-luciferase reporter assay
Site 1 (-909 to -915 bp) and Site 2 (-1018 to -1024 bp) in ABHD3 promoter, ABHD3 pro-
moter containing wildtype Site 2 (pro-WT) or mutant Site 2 (pro-MUT), wildtype YPEL3
and A539-mutated YPEL3 were cloned into the pGL3 vector (Promega, Madison, WI, USA)
as luciferase reporters. THLE-2 and AML12 cells were transfected with indicated luciferase
reporters and the MEOX1-overexpressing pcDNA3.1 vector or circABHD3-overexpressing
vector. Empty vector was used as a negative control. After 48 h, the luciferase activity was
examined with Dual-Glo Luciferase System (Promega).
PLOS Genetics | https://doi.org/10.1371/journal.pgen.1011622 March 18, 2025 6 / 29
PLOS GeneticS CircABHD3 exacerbates hepatic brosis via YPEL3-mediated β-catenin signaling
Chromatin Immunoprecipitation (ChIP)
THLE-2 and AML12 cells were crosslinked in 1% formaldehyde solution, washed, and lysed
in lysis buffer on ice. Cell lysates were collected and sonicated to obtain DNA fragments with
a length of ~500 bp. Anti-MEOX1 antibody (5 µg, sc-398845, Santa Cruz Biotechnology,
Dallas, TX, USA) and isotype control IgG were added into DNA fragments, and samples were
incubated for 16 h at 4°C. Protein A/G Magnetic Beads (Abcam) were added into samples, and
samples were incubated for 2 h. DNA was recovered and subjected to quantitative PCR.
RNA Pull-down assays
For RNA pull-down, biotin-conjugated circABHD3 and scramble sequences (Genepharma)
were mixed with the supernatants and incubated at 4°C for 5 h. The mixture was then mixed
with streptavidin-conjugated magnetic beads and incubated for 3 h. Magnetic beads were
washed, and protein-RNA complexes pulled down by the circABHD3 probe were used for
analyzing the abundance of YTHDF2 (1:1000, ab220163, Abcam).
A mouse model of hepatic fibrosis
Wildtype and circABHD3 knockout C57BL/6 mice (8-week-old, male, Cyagen Biosciences
Inc., Santa Clara, CA, USA) were divided into four groups: Vehicle, CCl4, CCl4 +
circABHD3-KO, CCl4 + circABHD3-KO + shNC and CCl4 + circABHD3-KO + shYPEL3. For
CCl4 treatment, mice were intraperitoneally injected with CCl4 (5%, 200 µL/kg body weight,
Sigma-Aldrich) in olive oil twice a week for six weeks [25]. Olive oil was injected into mice in
the Vehicle group. shYPEL3 lentiviral construct (Genepharma) was transduced into HEK293T
cells for packaging lentiviral particles. Lentivirus was harvested after 48 h, filtered, and
intravenously injected into mice (5 × 108 pfu/mouse) prior. Finally, serum was collected, and
mice were sacrificed. The livers were excised for Western blotting and histology and immu-
nohistochemistry staining. Animal procedures were approved by the Animal Care and Use
Committee of the Third Xiangya Hospital, Central South University (the approval number:
2021-S278).
Bile duct ligation (BDL) surgery
BDL surgery was performed as previously described with minor modification [26,27]. Briefly,
mice were anesthetized via isoflurane inhalation, and the common bile duct was isolated from
the flanking portal vein after a midline abdominal incision was made. Then, a non-resorbable
suture (silk 5-0) was used to occlude the bile duct via a double ligature. Mice received intra-
peritoneal injection of tramadol at 0.25 mg/kg. Mice were sacrificed after 4 weeks.
Histology and immunohistochemistry (IHC) staining
Liver samples from CCl4-induced hepatic fibrosis mice were immersed in 4% paraformalde-
hyde solution and fixed overnight at 4°C. Livers were dehydrated, embedded in paraffin, and
cut into 5-µm slices. Slices were then dewaxed and rehydrated. Subsequently, standard hema-
toxylin and eosin (H&E), Masson’s trichrome and Sirius Red staining were applied to exam-
ine liver injury, collagen deposition and fibrotic area in the livers. For IHC staining, antigen
was retrieved, and slices were sequentially blocked in 0.5% hydrogen peroxide solution and
5% BSA solution and incubated with rabbit α-smooth muscle actin (α-SMA, 1:100, ab5694),
β-catenin (1:200, ab223075), E-cadherin (1:100, 3195, Cell Signaling Technology, Danvers,
MA, USA) or N-cadherin (1:200, ab18203) antibodies overnight. Next day, a horseradish per-
oxidase (HRP)-conjugated goat anti-rabbit secondary antibody (1:5000, ab205718) was used
PLOS Genetics | https://doi.org/10.1371/journal.pgen.1011622 March 18, 2025 7 / 29
PLOS GeneticS CircABHD3 exacerbates hepatic brosis via YPEL3-mediated β-catenin signaling
to incubate sections. Diaminobenzidine (DAB, Solarbio) was applied for visualizing signals
prior to hematoxylin staining. Slices were mounted for imaging. Antibodies use in IHC assays
were purchase from Abcam unless otherwise indicated.
JC-1 staining
Mitochondrial membrane potential was evaluated by JC-1 (Thermo Fisher Scientific) staining.
JC-1 is a cationic dye that exhibits potential-dependent accumulation in mitochondria, indi-
cated by a fluorescence emission shift from green (~525 nm, JC-1 monomer) to red (~590 nm,
JC-1 aggregate). Thus, mitochondrial depolarization can be indicated by a decrease in the red/
green fluorescence ratio. Briefly, cells were transfected and treated as indicated. After wash,
cells were stained with JC-1 at 2 µM for 30 min and washed three times in PBS for imaging.
Enzyme-Linked Immunosorbent Assay (ELISA)
The levels of aspartate aminotransferase (AST) and alanine aminotransferase (ALT) in the
serum were determined using AST and ALT assay kits provided by Nanjing Jiancheng Bioen-
gineering Institute (Nanjing, Jiangsu, China) following the manufacturer’s recommendations.
The concentration of hydroxyproline (HYP) in the livers was measured using the HYP assay
kit (Nanjing Jiancheng Bioengineering Institute). The levels of 8-hydroxy 2 deoxyguanosine
(8-OHdG) in cell extracts and were examined with 8-hydroxy 2 deoxyguanosine ELISA Kit
(ab201734, Abcam).
Reactive oxygen species (ROS)
Cells were transfected and treated as indicated, washed, seeded in 96-well plates, and stained
with DCFH-DA Redox Probe (G-Biosciences, St. Louis, MO, USA) at 10 µM for 30 min. Then,
cells were washed three times in PBS, and the fluorescence was measured (Ex: 495 nm; Em:
529 nm) and normalized to the Control sample.
Transmission electron microscopy (TEM)
TEM was performed as previously described [28]. Briefly, liver samples were collected from
mice and immersed in 2.5% glutaraldehyde. Subsequenlty, samples were washed in PBS, fixed
in 1% osmium tetraoxide for 1 h and dehydrated in gradient ethanol solutions. Then, samples
were embedded, and ultrathin sections were prepared and stained with uranyl acetate and lead
citrate for imaging under a transmission electron microscope.
RNA extraction and qRT-PCR
Liver samples were homogenized, and Trizol reagent (Beyotime, Shanghai, China) was added
into the homogenates for RNA extraction. THLE-2 and AML12 cells were resuspended in
Trizol reagent, and total RNA was extracted followed by RNA quantification with the Nano-
drop spectrophotometer (Thermo Fisher Scientific). RNA was then reversely transcribed into
cDNA with HiScript II 1st Strand cDNA Synthesis Kit (Vazyme, Nanjing, Jiangsu, China),
which was subjected to quantitative PCR using SYBR Green Master Mix (Vazyme) for analyz-
ing the abundance of circABHD3, ABHD3, MEOX1, YPEL3, YTHDF2, Drp1, Fis1, OPA1 and
Mfn1. Gene expression was normalized to GAPDH and analyzed using the 2−∆∆Ct method.
Western blotting
Liver tissues were homogenized, resuspended in lysis buffer, and incubated at 4°C for
2 h prior to supernatant collection. THLE-2 and AML12 cells were lysed in lysis buffer
PLOS Genetics | https://doi.org/10.1371/journal.pgen.1011622 March 18, 2025 8 / 29
PLOS GeneticS CircABHD3 exacerbates hepatic brosis via YPEL3-mediated β-catenin signaling
on ice, and supernatants were collected after centrifugation. BCA Protein Assay Kit
(Solarbio) was used to quantify protein concentration. Protein (50 µg) was electro-
phoresed and transferred to polyvinylidene fluoride (PVDF) membranes, and mem-
branes were blocked and incubated with rabbit antibodies against α-SMA (1 µg/mL,
ab5694, Abcam), Collagen type I alpha 1 chain (COL1A1, 1:1000, ab260043, Abcam),
Snail (1:1000, 3879, Cell Signaling Technology, Danvers, MA, USA), E-cadherin
(1:1000, 3195, Cell Signaling Technology), N-cadherin (1 µg/mL, ab18203, Abcam),
Vimentin (1:1000, ab92547, Abcam), YTHDF2 (1:1000, ab220163, Abcam), GSK-3β
(1:500, ab131356, Abcam), β-catenin (1 µg/mL, ab223075, Abcam), phospho-β-catenin
(1:1000, 9561, Cell Signaling Technology), MEOX1 (1:500, PA5-21037, Thermo Fisher
Scientific), YPEL3 (1:1000, PA5-34349, Thermo Fisher Scientific) and GAPDH (1:2500,
ab9485, Abcam) overnight. Membranes were washed and incubated with an HRP-
conjugated goat anti-rabbit secondary antibody (1:25000, ab205718, Abcam) for 1 h.
Bands were visualized with enhanced chemiluminescence (ECL) substrate and analyzed
using Image J software.
Statistical analysis
Results from at least three independent assays were expressed as mean ± standard deviation
(SD). The variance of two and more groups was analyzed with the Student’s t test and One-
way analysis of variance (ANOVA). P < 0.05 was statistically significant.
Results
CircABHD3 was upregulated in hepatic fibrosis patients and research
models
As a previous study reported the upregulation of hsa_circ_0072437 (PARP8), hsa_
circ_0001147 (RBM39), hsa_circ_0047086 (ABHD3), hsa_circ_0010117 (SPEN) and
hsa_circ_0005325 (UBA2) in hepatic fibrosis tissues [29], we examined their expres-
sion in liver tissues from control donors and hepatic fibrosis patients, and found that
hsa_circ_0047086 (circAHBD3) showed highest expression (Fig 1A). Therefore, we
focused circABHD3 in this study. As shown in Fig 1B, circABHD3 (hsa_circ_0047086)
is 389 nucleotides in length and originates from the exon 6 to 8 of ABHD3 gene, and the
back-splicing site was identified through Sanger sequencing. Actinomycin D, a transcrip-
tion inhibitor, and RNase R were used to examine the stability of circABHD3. Compared
to ABHD3 mRNA, circABHD3 showed high stability after actinomycin D treatment and
excellent resistance to RNase R digestion (Fig 1C and 1D), exhibiting a typical stable
characteristic of circRNA. Moreover, we found that circABHD3 mainly localized in the
cytoplasm by nucleus and cytosol separation and FISH assays in THLE-2 and AML12
cells (Fig 1E and 1F). Compared to the signals of U6 snRNA and 18s rRNA, the signal
of circABHD3 was largely diminished after circABHD3 knockdown (Fig 1F). We further
found that fibrotic markers α-SMA and COL1A1 and the EMT-related marker Vimen-
tin were upregulated but E-cadherin was downregulated by TGF-β1 induction (Fig 1G).
Subsequently, we examined the expression levels of circABHD3 both in vivo and in vitro
models of liver fibrosis. We found that TGF-β1 could induce significant expression of
circABHD3 in hepatocyte cells, and in the liver tissue of mice with CCl4-induced fibro-
sis, circABHD3 expression was also significantly increased (Fig 1H and 1I). Moreover,
neither TGF-β1 nor CCl4 treatment affect the levels of ABHD3 mRNA, the precursor of
circABHD3 (S1A and S1B Fig). These data indicated that circABHD3 might be involved
in the pathogenesis of fibrosis.
PLOS Genetics | https://doi.org/10.1371/journal.pgen.1011622 March 18, 2025 9 / 29
PLOS GeneticS CircABHD3 exacerbates hepatic brosis via YPEL3-mediated β-catenin signaling
Fig 1. CircABHD3 was upregulated in hepatic fibrosis. (A) qRT-PCR analysis of hsa_circ_0072437, hsa_circ_0001147, hsa_circ_0047086, hsa_
circ_0010117 and hsa_circ_0005325 in liver samples from hepatic fibrosis (n = 8) and control (n = 8) patients. (B) Genomic loci of circABHD3
PLOS Genetics | https://doi.org/10.1371/journal.pgen.1011622 March 18, 2025 10 / 29
PLOS GeneticS CircABHD3 exacerbates hepatic brosis via YPEL3-mediated β-catenin signaling
Knockdown of circABHD3 significantly suppressed TGF-β1-induced EMT
and mitochondrial impairment in hepatocytes
Knockdown of circABHD3 was performed in THLE-2 and AML12 cells (Fig 2A), which was
followed by treatment with TGF-β1 to induce hepatic fibrosis to assess the impact of cir-
cABHD3 on the progression of liver fibrosis in these cell models. CircABHD3 was efficiently
knocked down, and no reduction in the level of ABHD3 was observed in THLE-2 and AML12
cells (Fig 2A). Results showed that the expression of EMT-related markers, such as Snail,
N-cadherin, and Vimentin, as well as fibrotic markers α-SMA and COL1A1, was upregulated
by TGF-β1 induction, while E-cadherin was downregulated (Fig 2B). However, knockdown of
circABHD3 abolished these effects (Fig 2B). IF staining showed that N-cadherin was upreg-
ulated but E-cadherin was downregulated, which was reversed by circABHD3 knockdown
(Fig 2C). Moreover, TGF-β1-induced increased levels of ROS and 8-OHdG, a DNA damage
marker, were inhibited by circABHD3 knockdown (Fig 2D and 2E). In addition, hepatic
fibrosis is associated with mitochondrial dysfunction, which can lead to hepatocyte dam-
age, immune cell activation, inflammation, and trans-differentiation of hepatic stellate cells
[30–32]. We found that TGF-β1-induced increased JC-1 monomer and decreased JC-1 aggre-
gate in TGF-β1-treated THLE-2 and AML12 cells were reduced by circABHD3 knockdown,
suggesting that circABHD3 knockdown suppressed TGF-β1-induced impaired mitochondrial
membrane potential (Fig 2F). Subsequently, we examined the expression of the mitochondrial
fission regulators Drp1 and Fis1 and fusion regulators OPA1 and Mfn1. TGF-β1-induced
upregulation of Drp1 and Fis1 and downregulation of OPA1 and Mfn1 were reversed by
knockdown of circABHD3 (Fig 2G). In aggregate, our data indicated that the inhibition of
circABHD3 suppressed TGF-β1-induced EMT and mitochondrial dynamic imbalance in
hepatocyte cells.
MEOX1 facilitated circABHD3 expression via binding to the promoter of
ABHD3 in THLE-2 and AML12 cells
Given the significant involvement of MEOX1 in fibrosis, we examined MEOX1 expression
in hepatic fibrosis tissues from patients. MEOX1 was highly expressed, and its expression
was positively correlated with circABHD3 expression in hepatic fibrosis tissues (Fig 3A and
3B). TGF-β1 treatment significantly upregulated MEOX1 expression at both the mRNA and
protein levels in hepatocyte cells (Fig 3C and 3D). As mentioned above, circABHD3 promotes
EMT and mitochondrial impairment in hepatocytes. However, the mechanisms underlying
circABHD3 upregulation remain unclear. It is known that circRNAs are transcribed, spliced,
and subsequently cyclized from host genes, and host genes promote circRNA generation
[33,34]. Host genes can produce circRNAs through back-splicing of exons. Moreover, the
3′-untranslated regions (3′ UTRs) of cognate mRNAs can be bound by other regulators such
as ZC3H14 to promote circRNA biogenesis [35]. Therefore, elucidating the mechanisms of
ABHD3 transcription may contribute to understanding circABHD3 generation. Intriguingly,
and its formation via back-splicing. The junction site was identified by Sanger sequencing. (C and D) The abundance of circABHD3 and ABHD3
mRNA after actinomycin D and RNase R treatment (n = 3). (E) The abundance of circABHD3, MALAT1 (the nuclear reference), U6 (the nuclear
reference), Mt-COI (the cytoplastic reference), and GAPDH (the cytoplastic reference) in the nucleus and cytoplasm. (F) THLE-2 and AML12
cells were transfected with shNC or shcircABHD3, and the localization of U6 snRNA (red, the nuclear reference), 18s rRNA (red, the cytoplastic
reference) and circABHD3 (red) was examined by FISH. DAPI was used to stain the nuclei (blue). Scale bar, 25 µm. (G) THLE-2 and AML12
cells were treated with TGF-β1 at 5 ng/mL for 48 h. Protein levels of α-SMA, COL1A1, E-cadherin, and Vimentin were detected with Western
blotting (n = 3). (H and I) qRT-PCR analysis of circABHD3 in TGF-β1 or vehicle-treated cells (n = 3) and CCl4 or vehicle-treated mice (n = 6).
**P < 0.01 and ***P < 0.001.
https://doi.org/10.1371/journal.pgen.1011622.g001
PLOS Genetics | https://doi.org/10.1371/journal.pgen.1011622 March 18, 2025 11 / 29
PLOS GeneticS CircABHD3 exacerbates hepatic brosis via YPEL3-mediated β-catenin signaling
Fig 2. Knockdown of circABHD3 significantly suppressed TGF- β1-induced EMT and mitochondrial impairment in hepatocytes. THLE-2 and AML12 cells
were treated with TGF-β1 at 5 ng/mL for 48 h and divided into four groups: Control, TGF-β1, TGF-β1 + shNC and TGF-β1 + shcircABHD3. (A) The levels of
PLOS Genetics | https://doi.org/10.1371/journal.pgen.1011622 March 18, 2025 12 / 29
PLOS GeneticS CircABHD3 exacerbates hepatic brosis via YPEL3-mediated β-catenin signaling
we identified two potential binding sites (Site1 and Site2) for MEOX1 in the promoter region
of ABHD3 (Fig 3E). MEOX1 was overexpressed or knocked down in THLE-2 and AML12
cells (Fig 3F and 3G). Overexpression of MEOX1 enhanced the luciferase activity of the Site2
reporter but did not affect the luciferase activity of the Site1 reporter (Fig 3H). Besides, over-
expression of MEOX1 enhanced the luciferase activity of the ABHD3 pro-WT reporter but
did not affect the luciferase activity of the ABHD3 pro-MUT reporter (Fig 3I). Furthermore,
the ABHD3 promoter was efficiently enriched by the antibody against MEOX1 (Fig 3J). As
shown in Fig 3K, we designed primers to examine the expression of pre-ABHD3, ABHD3 and
circABHD3, and they were all upregulated by overexpression of MEOX1 (Fig 3L). Moreover,
silencing of MEOX1 significantly reduced the expression of pre-ABHD3, ABHD3 and cir-
cABHD3 (Fig 3L). These observations suggested that MEOX1 might promote the expression
of ABHD3 mRNA by binding to the ABHD3 promoter, consequently increasing circABHD3
in hepatic fibrosis.
MEOX1 knockdown inhibited EMT and mitochondrial impairment
in TGF-β1-treated THLE-2 and AML12 cells through suppression of
circABHD3
To evaluate whether MEOX1 regulates TGF-β1-induced EMT and mitochondrial imbal-
ance through circABHD3, MEOX1 was knocked down and circABHD3 was overexpressed
in THLE-2 and AML12 cells, which was confirmed by qRT-PCR and Western blotting (Fig
4A-C). TGF-β1-induced upregulation of α-SMA, COL1A1, Snail, N-cadherin and Vimentin
and downregulation of E-cadherin were obstructed by MEOX1 knockdown, but simultane-
ous overexpression of circABHD3 restored their expression (Fig 4D). IF staining showed that
TGF-β1-induced E- to N-cadherin transition was inhibited by MEOX1 knockdown, which
was reversed by overexpression of circABHD3 (Fig 4E). Furthermore, increased levels of ROS
and 8-OHdG and impaired mitochondrial membrane potential in TGF-β1-treated THLE-2
and AML12 cells were reduced by MEOX1 knockdown, and overexpression of circABHD3
abolished MEOX1 knockdown-mediated effects (Fig 4F-H). Besides, knockdown of MEOX1
reduced the expression of Drp1 and Fis1 but enhanced the expression of OPA1 and Mfn1 in
TGF-β1-treated THLE-2 and AML12 cells, but their expression was reversed by circABHD3
overexpression (Fig 4I). Thus, these data suggested that knockdown of MEOX1 suppressed
TGF-β1-induced EMT and mitochondrial impairment dependent on circABHD3 in THLE-2
and AML12 cells.
CircABHD3 destabilized YPEL3 mRNA to activate β-catenin signaling in
TGF-β1-treated THLE-2 and AML12 cells
As YPEL3 can be induced by DNA damage and YPEL3 inhibits EMT of nasopharyngeal
carcinoma cells via Wnt/β-catenin signaling [17,36], However, the role of YPEL3 and its reg-
ulation of EMT in liver fibrosis was unknown. Thus, to investigate the mechanism by which
circABHD3 regulates EMT in liver fibrosis, we decided to examine its expression in TGF-β1-
treated THLE-2 and AML12 cells. We observed that YPEL3 was downregulated in TGF-β1-
treated THLE-2 and AML12 cells, but the suppressive effect was abrogated by circABHD3
circABHD3 and ABHD3 mRNA in THLE-2 and AML12 cells were detected by qRT-PCR (n = 3). (B) Protein levels of α-SMA, COL1A1, Snail, E-cadherin, N-
cadherin, and Vimentin were detected with Western blotting (n = 3). GAPDH was a loading control for normalization. (C) IF staining of E-cadherin (green) and
N-cadherin (red). DAPI was used to stain the nuclei (blue). Scale bar, 100 µm. (D) The ROS level was determined (n = 3). (E) The level of 8-OHdG was examined
(n = 3). (F) Mitochondrial membrane potential was examined with JC-1 staining (n = 3). JC-1 monomer, green; JC-1 aggregate, red. Scale bar, 100 µm. (G) The
expression of Drp1, Fis1, OPA1 and Mfn1 was analyzed by qRT-PCR (n = 3). *P < 0.05 and **P < 0.01.
https://doi.org/10.1371/journal.pgen.1011622.g002
PLOS Genetics | https://doi.org/10.1371/journal.pgen.1011622 March 18, 2025 13 / 29
PLOS GeneticS CircABHD3 exacerbates hepatic brosis via YPEL3-mediated β-catenin signaling
Fig 3. MEOX1 facilitated circABHD3 expression via binding to the promoter of ABHD3 in THLE-2 and AML12 cells. (A) qRT-PCR analysis of
MEOX1 mRNA in liver samples from hepatic fibrosis (n = 8) and control (n = 8) patients. (B) The correlation analysis of the expression of MEOX1 and
PLOS Genetics | https://doi.org/10.1371/journal.pgen.1011622 March 18, 2025 14 / 29
PLOS GeneticS CircABHD3 exacerbates hepatic brosis via YPEL3-mediated β-catenin signaling
knockdown (Fig 5A and 5B), suggesting the involvement of circABHD3 in the regulation of
TGF-β1-induced downregulation of YPEL3. As YPEL3 suppresses EMT through the Wnt/β-
catenin signaling pathway [17], we examined the levels of GSK-3β, a negative regulator of
the Wnt/β-catenin signaling pathway, β-catenin and phosphorylated β-catenin. The levels of
GSK-3β and β-catenin phosphorylation were decreased, but the abundance of total β-catenin
was increased in response to TGF-β1 treatment, whereas circABHD3 knockdown reversed
these effects (Fig 5B), suggesting that circABHD3 knockdown blocked TGF-β1-mediated
activation of β-catenin signaling. Additionally, we analyzed the m6A modification of YPEL3
mRNA, as it is widely known to be involved in mRNA degradation. We found two m6A mod-
ification sites on YPEL3 mRNA by SRAMP database analysis (with the highest confidence
in its A539 site, Fig 5C). The treatment with TGF-β1 led to an increase in m6A modification
levels of YPEL3 mRNA in hepatocyte cells (Fig 5D). Overexpression of circABHD3 reduced
YPEL3 mRNA luciferase activity, whereas it had no significant effect on YPEL3 mRNA lucif-
erase activity with the A539 site mutation (Fig 5E). The treatment with TGF-β1 significantly
reduced the stability of YPEL3 mRNA (Fig 5F). TGF-β1-induced m6A modification of YPEL3
mRNA and subsequent decreased YPEL3 RNA stability were blocked by knockdown of cir-
cABHD3 (Fig 5D and 5F). Thus, circABHD3 might destabilize YPEL3 mRNA and inhibit its
expression, thereby activating β-catenin signaling in hepatic fibrosis.
CircABHD3 promoted YTHDF2-dependent recognition of m6A-modified
YPEL3 mRNA to destabilize YPEL3 mRNA and reduced the expression of
YPEL3 and GSK-3β
The level of m6A is primarily modulated by m6A writers and erasers, while m6A readers can
recognize m6A and regulate mRNA translation and stability [37]. Therefore, we assessed the
enrichment of YPEL3 mRNA by employing antibodies that specifically target various m6A
reader proteins, such as YTHDC1, YTHDC2, YTHDF1, YTHDF2, YTHDF3, and HNRNPC.
The IP efficiencies among anti-YTHDC1, anti-YTHDC2, anti-YTHDF1, anti-YTHDF2,
anti-YTHDF3 and anti-HNRNPC were almost similar (S 2A Fig). Our results indicated
that the YTHDF2 antibody exhibited the greatest enrichment of YPEL3 mRNA (Fig 6A).
CircABHD3 rather than ABHD3 and GAPDH mRNA could be efficiently pulled down by
the circABHD3 probe (S2B Fig). The results of circABHD3 pull-down assay demonstrated
the presence of YTHDF2 in the products pulled down by the circABHD3 probe (Fig 6B).
The YTHDF2 antibody RIP experiment also confirmed the binding relationship between
YTHDF2 and circABHD3 (Fig 6C), and no significant co-
immunoprecipitation of ABHD3 mRNA was observed (S3 Fig). Furthermore, FISH and
IF co-staining in THLE-2 and AML12 cells proved the co-localization relationship of
circABHD3 and YTHDF2, and the signal of circABHD3 was dramatically reduced after
circABHD3 knockdown (Fig 6D). These data support the hypothesis that circABHD3 may
participate in YPEL3 mRNA stability regulation through its interaction with YTHDF2.
YTHDF2 consists of a C-terminal YTH structural domain responsible for binding to m6A
and an N-terminal structural domain enriched with P/Q/N (Fig 6E). The main function
circABHD3 in liver samples from hepatic fibrosis patients. (C and D) The expression of MEOX1 in control and TGF-β1-treated THLE-2 and AML12 cells
was examined with qRT-PCR and Western blotting (n = 3). (E) Two potential binding sites for MEOX1 in the promoter of ABHD3. (F and G) MEOX1 was
overexpressed or knocked down in THLE-2 and AML12 cells, and its expression was examined by qRT-PCR and Western blotting (n = 3). (H and I) The
luciferase activity of Site1, Site2, ABHD3 pro-WT or ABHD3 pro-MUT reporters in THLE-2 and AML12 cells transfected with vector or MEOX1 (n = 3).
(J) The enrichment of ABHD3 promoter by the MEOX1 antibody was determined with ChIP assays (n = 3). (K) Primers for ABHD3 pre-RNA, mRNA
and circABHD3. (L) qRT-PCR analysis of ABHD3 pre-RNA, mRNA and circABHD3 in cells transfected with vector, MEOX1, shNC or shMEOX1 (n = 3).
*P < 0.05, **P < 0.01 and ***P < 0.001.
https://doi.org/10.1371/journal.pgen.1011622.g003
PLOS Genetics | https://doi.org/10.1371/journal.pgen.1011622 March 18, 2025 15 / 29
PLOS GeneticS CircABHD3 exacerbates hepatic brosis via YPEL3-mediated β-catenin signaling
Fig 4. MEOX1 knockdown inhibited EMT and mitochondrial impairment in TGF- β1-treated THLE-2 and AML12 cells. MEOX1
was knocked down and circABHD3 was overexpressed in THLE-2 and AML12 cells, and cells were treated with with TGF-β1 at 5 ng/
PLOS Genetics | https://doi.org/10.1371/journal.pgen.1011622 March 18, 2025 16 / 29
PLOS GeneticS CircABHD3 exacerbates hepatic brosis via YPEL3-mediated β-catenin signaling
of the C-terminal YTH structural domain is to recognize and bind to m6A-modified RNA
molecules, and to participate in the regulation of the metabolism of RNAs, including mRNA
translation and stability. We constructed different truncated vectors of YTHDF2 to deter-
mine the specific binding for sites of circABHD3 and YTHDF2 (Fig 6E). The results showed
that circABHD3 was significantly enriched by YTHDF2, YTHDF2∆C and
YTHDF2∆N201-400 rather than YTHDF2∆N and YTHDF2∆N1-200 (Fig 6F), suggesting
that circABHD3 primarily bound to 1-200 in the N-terminal region of YTHDF2. Subse-
quently, to investigate the regulation of YPEL3 mRNA stability by YTHDF2, YTHDF2 was
knocked down in THLE-2 and AML12 cells, and we observed a significant increase in YPEL3
expression (Fig 6G–I). Furthermore, YPEL3 mRNA could be enriched by the YTHDF2
antibody, and circABHD3 overexpression enhanced the enrichment (Fig 6J). Knockdown
of YTHDF2 impaired the inhibitory effect of circABHD3 overexpression on YPEL3 mRNA
luciferase activity (Fig 6K). Overexpression of circABHD3 accelerated the decay of YPEL3
mRNA to reduce YPEL3 expression, but it was reversed by YTHDF2 knockdown (Fig 6L
and 6M). In addition, overexpression of circABHD3 reduced the protein levels of YPEL3,
GSK-3β and phosphorylated β-catenin and promoted the expression of total β-catenin in
THLE-2 and AML12 cells, but knockdown of YTHDF2 reversed their expression patterns
(Fig 6N). Therefore, we concluded that circABHD3 promoted YTHDF2 binding to YPEL3 to
facilitate YTHDF2-mediated YPEL3 mRNA decay, subsequently reducing the expression of
YPEL3 and GSK-3β and leading to the activation of β-catenin signaling.
Knockdown of YPEL3 or activation of β-catenin reversed circABHD3
silencing-mediated prevention of EMT and mitochondrial impairment in
TGF-β1-induced hepatocytes
YPEL3 was knocked down in THLE-2 and AML12 cells, and its knockdown was confirmed
by qRT-PCR and Western blotting (Fig 7A and 7B). THLE-2 and AML12 cells were trans-
fected with shcircABHD3 and shYPEL3 and treated with lithium chloride (LiCl) for induce
activation of β-catenin signaling. Cells were divided into TGF-β1 + shNC, TGF-β1 + shcir-
cABHD3, TGF-β1 + shcircABHD3 + shNC, TGF-β1 + shcircABHD3 + shYPEL3 and TGF-
β1 + shcircABHD3 + LiCl groups. The results demonstrated that silencing of circABHD3
significantly reduced the expression of α-SMA, COL1A1, Snail, N-cadherin and Vimentin
and upregulated E-cadherin, but these effects were reversed by YPEL3 knockdown or LiCl
treatment (Fig 7C and 7D). Besides, circABHD3 knockdown-mediated suppressive effects
on the levels of ROS and 8-OHdG and mitochondrial membrane potential depolarization
in TGF-β1-treated THLE-2 and AML12 cells were abolished by YPEL3 knockdown or
LiCl treatment (Fig 7E–G). Drp1 and Fis1 were downregulated and OPA1 and Mfn1 were
upregulated by circABHD3 knockdown, which was reversed by YPEL3 knockdown or LiCl
treatment (Fig 7H). Thus, the relief of TGF-β1-induced EMT and mitochondrial imbalance
resulting from circABHD3 silencing was dependent on YPEL3 and subsequent inhibition of
β-catenin signaling.
mL for 48 h. (A and B) THLE-2 and AML12 cells were transfected with shNC, shMEOX1#1, shMEOX1#2 or shMEOX1#3, and MEOX1
was detected via qRT-PCR and Western blotting (n = 3). (C) THLE-2 and AML12 cells were transfected with Vector or circABHD3, and
circABHD3 was examined by qRT-PCR (n = 3). (D) Protein levels of α-SMA, COL1A1, Snail, E-cadherin, N-cadherin, and Vimentin
were detected with Western blotting (n = 3). GAPDH was a loading control for normalization. (E) IF staining of E-cadherin (green) and
N-cadherin (red). DAPI was used to stain the nuclei (blue). Scale bar, 100 µm. (F) The ROS level was determined (n = 3). (G) The level of
8-OHdG was examined (n = 3). (H) Mitochondrial membrane potential was examined with JC-1 staining (n = 3). JC-1 monomer, green;
JC-1 aggregate, red. Scale bar, 100 µm. (I) The expression of Drp1, Fis1, OPA1 and Mfn1 was analyzed by qRT-PCR (n = 3). *P < 0.05 and
**P < 0.01.
https://doi.org/10.1371/journal.pgen.1011622.g004
PLOS Genetics | https://doi.org/10.1371/journal.pgen.1011622 March 18, 2025 17 / 29
PLOS GeneticS CircABHD3 exacerbates hepatic brosis via YPEL3-mediated β-catenin signaling
Fig 5. CircABHD3 destabilized YPEL3 mRNA to activate β-catenin signaling in TGF-β1-treated THLE-2 and AML12 cells. THLE-2 and AML12 cells were
treated with TGF-β1 at 5 ng/mL for 48 h and divided into four groups: Control, TGF-β1, TGF-β1 + shNC and TGF-β1 + shcircABHD3. (A) Relative mRNA levels of
YPEL3 were examined by qRT-PCR (n = 3). (B) Protein levels of YPEL3, GSK-3β, total and phosphorylated β-catenin were detected with Western blotting (n = 3).
GAPDH was a loading control for normalization. (C) m6A modification sites on YPEL3 mRNA was analyzed by SRAMP database analysis. (D) MeRIP assays
PLOS Genetics | https://doi.org/10.1371/journal.pgen.1011622 March 18, 2025 18 / 29
PLOS GeneticS CircABHD3 exacerbates hepatic brosis via YPEL3-mediated β-catenin signaling
Depletion of circABHD3 ameliorated hepatic fibrosis in mice
Mice were divided into five groups: Vehicle, CCl4, CCl4 + circABHD3-KO, CCl4 + circABHD3-
KO + shNC and CCl4 + circABHD3-KO + shYPEL3. CCl4 was intraperitoneally injected into
mice for liver fibrosis induction. As expected, CCl4-treated wildtype mice showed obvious
liver injury and increased collagen deposition and fibrotic areas, as exhibited by H&E, Mas-
son’s trichrome and Sirius Red staining, accompanied by an elevation in α-SMA protein levels,
demonstrating the effectiveness of the liver fibrosis induction in mice (Fig 8A). However,
no significant CCl4-induced damage was observed in circABHD3 knockout mice (Fig 8A).
Importantly, circABHD3 depletion-mediated protection was abolished by YPEL3 knockdown
(Fig 8A). Meanwhile, the pathological elevation of serum ALT, AST, and hydroxyproline
(HYP) induced by CCl4 treatment were significantly blocked by circABHD3 knockout, but
these protective effects were reversed by YPEL3 knockdown (Fig 8B–D). CCl4-treated mice
showed decreased expression of YPEL3, GSK-3β and phosphorylated β-catenin and elevated
expression of total β-catenin, α-SMA and COL1A1 in the livers, whereas depletion of cir-
cABHD3 reversed their expression, and knockdown of YPEL3 abolished these effects (Fig 8E
and 8F). Thus, depletion of circABHD3 suppressed CCl4-induced hepatic fibrosis dependent
on YPEL3 upregulation and subsequent suppression of β-catenin signaling in mice.
Depletion of circABHD3 inhibited CCl4-induced EMT and mitochondrial
impairment dependent on YPEL3 in mice
We further examined the expression of EMT-related markers and found that the expression
of Snail, Vimentin and N-cadherin were enhanced and E-cadherin was downregulated in the
livers from CCl4-treated mice, but these changes were reversed by circABHD3 depletion, and
circABHD3 depletion-mediated protective effects on CCl4-induced EMT was abrogated by
YPEL3 knockdown (Fig 9A and 9B). Depletion of circABHD3 reduced the levels of 8-OHdG,
Drp1 and Fis1 upregulated OPA1 and Mfn1 in CCl4-treated mice, which was abolished
by YPEL3 knockdown (Fig 9C and 9D). In addition, CCl4-treated mice showed shortened
mitochondrial length and increased mitochondrial density, and these changes were inhibited
by depletion of circABHD3 (Fig 9E). However, depletion of circABHD3-mediated effects on
mitochondrial morphology and fission were reversed by YPEL3 knockdown (Fig 9E). We also
established the bile duct ligation (BDL) model of hepatic fibrosis and found that BDL mice
showed obvious liver injury and increased collagen deposition, fibrotic areas and α-SMA,
which were reversed by knockdown of circABHD3 (S4A Fig). Increased levels of ALT, AST
and HYP in BDL mice were reduced by circABHD3 depletion (S4B-D Fig). Increased ratio of
N-cadherin-positive cells and decreased ratio of E-cadherin-positive cells in BDL mice were
reduced by depletion of circABHD3 (S4E Fig). Collectively, these findings implied that deple-
tion of circABHD3 inhibited CCl4-induced EMT and mitochondrial impairment through
YPEL3 in vivo.
Discussion
Although it has few symptoms, hepatic fibrosis is still a serious health issue worldwide as
it results in liver cirrhosis and carcinoma [38]. Liver cirrhosis is the end stage of fibrosis,
and around one million deaths a year are caused by liver cirrhosis and its complications
for analyzing m6A modification of YPEL3 mRNA (n = 3). (E) The luciferase activity of YPEL3 reporters in THLE-2 and AML12 cells transfected with vector or
circABHD3 (n = 3). (F) Remaining YPEL3 mRNA at 0, 4, 8 and 12 h in THLE-2 and AML12 cells after actinomycin D treatment was analyzed by qRT-PCR (n = 3).
*P < 0.05, **P < 0.01 and ***P < 0.001.
https://doi.org/10.1371/journal.pgen.1011622.g005
PLOS Genetics | https://doi.org/10.1371/journal.pgen.1011622 March 18, 2025 19 / 29
PLOS GeneticS CircABHD3 exacerbates hepatic brosis via YPEL3-mediated β-catenin signaling
Fig 6. CircABHD3 promoted YTHDF2-dependent recognition of m6A-modified YPEL3 mRNA to destabi-
lize YPEL3 mRNA and reduced the expression of YPEL3 and GSK-3 β. (A) The enrichment of YPEL3 mRNA by
PLOS Genetics | https://doi.org/10.1371/journal.pgen.1011622 March 18, 2025 20 / 29
PLOS GeneticS CircABHD3 exacerbates hepatic brosis via YPEL3-mediated β-catenin signaling
globally [39]. Fortunately, growing evidence suggests that hepatic fibrosis is reversible
in both patients and experimental fibrotic models [40,41]. It is of great importance to
further understand the pathogenesis of hepatic fibrosis and develop novel medications
for hepatic fibrosis management. Here, we found that circABHD3 exacerbated hepatic
fibrosis via promoting EMT and mitochondrial impairment in liver fibrosis. Mechani-
cally, circABHD3 destabilized YPEL3 mRNA through promotion of YTHDF2-mediated
degradation of YPEL3 mRNA, thus activating β-catenin signaling. In addition, MEOX1
could bound to the promoter of ABHD3 to enhance its transcription and subsequent
circABHD3 generation.
The onset and progression of hepatic fibrosis are quite complicated processes, in which
EMT has been shown to be a contributor in many studies [12]. Zeisberg et al. demonstrated
that hepatocyte-derived fibroblasts via undergoing EMT promoted the progression of hepatic
fibrosis, supporting the concept that EMT in hepatocytes contributes to hepatic fibrosis
[42]. However, several studies suggest that the roles of EMT in hepatic fibrosis remain under
debate [43]. A study challenged the notion that hepatocytes underwent EMT to generate ECM
proteins in hepatic fibrosis [44]. Chu et al. found that cholangiocytes and hepatocytes did not
undergo EMT in liver fibrosis mouse models [45]. Further extensive investigations need to
be conducted to reconcile these conflicting data. Our findings support the concept that EMT
contributes to hepatic fibrosis, and blockade of EMT may be a therapeutic strategy for fibrosis
intervention.
CircRNAs are emerging as important regulators in EMT and hepatic fibrosis. cir-
cUHRF1 was reported to enhance EMT in oral squamous cell carcinoma [46]. Xu et al.
found that hsa_circ_0003288 promoted EMT in liver cancer [47]. Several circRNAs are
implicated in the progression of hepatic fibrosis [48]. Wang et al. reported that circ-
MTO1 suppressed hepatic fibrosis by modulating miR‐17‐5p and Smad7 [49]. Zhu and
colleagues proved that circUbe2k enhanced liver fibrosis through the miR-149-5p/TGF-
β2 axis [50]. However, circRNA-mediated linkage between EMT and hepatic fibrosis
remains largely unknown. In our study, we found that circABHD3 was highly expressed
in hepatic fibrosis tissues and models, and circABHD3 exacerbated CCl4-induced liver
injury and fibrosis through promotion of EMT in vivo, suggesting a novel mechanism
underlying circRNA-mediated regulation of hepatic fibrosis via EMT. Besides, the
upstream regulatory mechanisms underlying circRNA generation are key to understand
the roles of circRNAs in various pathological conditions. CircRNAs are derived from
host genes, and host genes facilitate corresponding circRNA generation by back-splicing
anti-YTHDC1, anti-YTHDC2, anti-YTHDF1, anti-YTHDF2, anti-YTHDF3 and anti-HNRNPC was determined by RIP-
qPCR analysis (n = 3). Normal IgG was used as the negative control. (B) YTHDF2 was pulled down by the circABHD3
probe and subjected for electrophoresis. (C) CircABHD3 was enriched by an YTHDF2 antibody and subjected to qRT-
PCR and electrophoresis (n = 3). (D) Colocalization analysis of circABHD3 and YTHDF2 through combined FISH and
IF staining in shNC and shcircABHD3-transfected THLE-2 and AML12 cells. DAPI was used to stain the nuclei (blue).
Scale bar, 25 µm. (E) Various truncated constructs of YTHDF2 including YTHDF2∆C, YTHDF2∆N, YTHDF2∆N1-200
and YTHDF2∆N201-400. (F) CircABHD3 was enriched and subjected to qRT-PCR (n = 3). (G and H) YTHDF2 was
knocked down in THLE-2 and AML12 cells, and relative mRNA levels of YTHDF2 and YPEL3 were analyzed by qRT-
PCR (n = 3). (I) Western blot analysis of YTHDF2 and YPEL3 (n = 3). GAPDH was a loading control for normalization.
(J) THLE-2 and AML12 cells were transfected with vector or circABHD3, and the enrichment of YPEL3 by the YTHDF2
antibody was analyzed by RIP-qPCR (n = 3). THLE-2 and AML12 cells were divided into four groups: Vector, cir-
cABHD3, circABHD3 + shNC and circABHD3 + shYTHDF2. (K) The luciferase activity of YPEL3 reporters in THLE-2
and AML12 cells transfected with circABHD3 or shYTHDF2 (n = 3). (L) Remaining YPEL3 mRNA at 0, 4, 8 and 12 h
after actinomycin D treatment was analyzed by qRT-PCR (n = 3). (M) Relative mRNA levels of YPEL3 were examined by
qRT-PCR (n = 3). (N) Protein levels of YPEL3, GSK-3β, phosphorylated and total β-catenin were detected with Western
blotting (n = 3). GAPDH was a loading control for normalization. *P < 0.05, **P < 0.01 and ***P < 0.001.
https://doi.org/10.1371/journal.pgen.1011622.g006
PLOS Genetics | https://doi.org/10.1371/journal.pgen.1011622 March 18, 2025 21 / 29
PLOS GeneticS CircABHD3 exacerbates hepatic brosis via YPEL3-mediated β-catenin signaling
Fig 7. Knockdown of YPEL3 or activation of β-catenin reversed circABHD3 silencing-mediated prevention of EMT and mitochondrial
impairment in TGF-β1-induced hepatocytes. (A and B) Relative mRNA and protein levels of YPEL3 in shNC or shYPEL3-transfected THLE-2
PLOS Genetics | https://doi.org/10.1371/journal.pgen.1011622 March 18, 2025 22 / 29
PLOS GeneticS CircABHD3 exacerbates hepatic brosis via YPEL3-mediated β-catenin signaling
involving other regulators such as ZC3H14-mediated promotion of circRNA biogenesis
by facilitating back-splicing, thus producing a positive feedback loop for the regulation
of circRNAs and host genes [33, 34]. We identified a novel regulatory mechanism of
circABHD3 generation that MEOX1 can bind to ABHD3 promoter to facilitate ABHD3
transcription and circABHD3 generation, thus exacerbates EMT and mitochondrial
impairment through circABHD3. Emerging evidence has suggested that many circRNAs
are differentially expressed in liver fibrotic tissues, and circRNAs are highly abundant
in blood [51,52]. Thus, circRNAs may be developed as reliable biomarkers of diseases
and treatment efficacy due to their highly stable nature and remarkable tissue specificity.
Our findings provide evidence for circABHD3 as a potential diagnostic and prognostic
markers and therapeutic target for liver fibrosis.
YTHDF2, a m6A reader, enhances the degradation of mRNAs via binding to
m6A-modified mRNAs [53,54]. For example, YTHDF2 targets and destabilizes
m6A-modified mRNAs such as neural-specific genes [55]. Besides, YTHDF2 also
regulates mRNA decay through other mechanisms such as 5′-to-3′ decay and inter-
nal cleavage, and YTHDF2 triggers rapid degradation of m6A-containing mRNAs by
recognizing m6A and recruiting RNA-degrading enzymes or adaptor proteins [56,57].
A preprint reported that METTL3 promoted the progression of hepatic fibrosis
through YTHDF2-mediated silencing of GPR161 in a m6A-dependent manner [58].
Reduced EMT was observed in YTHDF2-deleted Hela cells [59], and overexpression of
YTHDF2 enhanced EMT in lung squamous cell carcinoma cells [60]. Consistently, for
the first time, we confirmed that YTHDF2 recognized m6A-YPEL3 mRNA to enhance
its degradation. Therefore, circABHD3 destabilized YPEL3 mRNA through YTHDF2
in a m6A-dependent manner, thus promoting EMT and hepatic fibrosis.
The β-catenin signaling contributes to the initiation of EMT via its nuclear transloca-
tion and regulating the expression of downstream target genes in various fibrotic diseases
[61,62]. β-catenin can be phosphorylated by GSK-3β for ubiquitin-mediated degradation
that is vital for suppressing the activation of β-catenin signaling [63]. In addition, YPEL3, a
member of the putative zinc finger motif, is emerging as a negative regulator of β-
catenin signaling to suppress EMT in cancer [17]. YPEL3 has been reported to inhibit
tumor proliferation, metastasis and growth [64], but its roles in hepatic fibrosis are
unknown. We found that circABHD3 facilitated the decay of YPEL3 mRNA in a m6A/
YTHDF2 dependent manner, leading to GSK-3β downregulation and inactivation of β-
catenin signaling in liver fibrosis.
Taken together, we firstly demonstrated that MEOX1-regulated circABHD3 exacerbated
hepatic fibrosis via promoting EMT and mitochondrial through suppression of YPEL3-
mediated inactivation of β-catenin signaling in a YTHDF2-dependent manner. Our results
not only deepen understanding of the pathogenesis of hepatic fibrosis but also suggests
potential therapeutic targets. However, to do this, more clinical samples should be included in
further investigations.
and AML12 cells were examined with qRT-PCR and Western blotting (n = 3). THLE-2 and AML12 cells were divided into five groups: TGF-
β1 + shNC, TGF-β1 + shcircABHD3, TGF-β1 + shcircABHD3 + shNC, TGF-β1 + shcircABHD3 + shYPEL3 and TGF-β1 + shcircABHD3 + LiCl.
(C) Western blot analysis of α-SMA, COL1A1, Snail, E-cadherin, N-cadherin, and Vimentin (n = 3). GAPDH was a loading control for nor-
malization. (D) IF staining of E-cadherin (green) and N-cadherin (red) for evaluating cadherin switching (n = 3). DAPI was used to stain the
nuclei (blue). Scale bar, 100 µm. (E) The ROS level was determined (n = 3). (F) The level of 8-OHdG was examined (n = 3). (G) Mitochondrial
membrane potential was examined with JC-1 staining (n = 3). JC-1 monomer, green; JC-1 aggregate, red. Scale bar, 100 µm. (H) The expression
of Drp1, Fis1, OPA1 and Mfn1 was analyzed by qRT-PCR (n = 3). *P < 0.05, **P < 0.01 and ***P < 0.001.
https://doi.org/10.1371/journal.pgen.1011622.g007
PLOS Genetics | https://doi.org/10.1371/journal.pgen.1011622 March 18, 2025 23 / 29
PLOS GeneticS CircABHD3 exacerbates hepatic brosis via YPEL3-mediated β-catenin signaling
Fig 8. Depletion of circABHD3 ameliorated hepatic fibrosis in mice. Wildtype and circABHD3 knockout (KO) mice were intraperitoneally injected
with CCl4 for hepatic fibrosis induction and divided into five groups: Vehicle, CCl4, CCl4 + circABHD3-KO, CCl4 + circABHD3-KO + shNC and
PLOS Genetics | https://doi.org/10.1371/journal.pgen.1011622 March 18, 2025 24 / 29
PLOS GeneticS CircABHD3 exacerbates hepatic brosis via YPEL3-mediated β-catenin signaling
Supporting information
S1 Fig. The level of ABHD3 mRNA was not affected by TGF-β1 or CCl4 treatment.
THLE-2 and AML12 cells were treated with TGF-β1 at 5 ng/mL for 48 h and divided into
two groups: Control and TGF-β1. (A) qRT-PCR analysis of ABHD3 mRNA in TGF-β1 or
vehicle-treated cells (n = 3). Mice were treated with CCl4 or vehicle, and qRT-PCR analysis of
ABHD3 mRNA in CCl4 or vehicle-treated mice (n = 6).
(TIF)
S2 Fig. The IP efficiencies of RIP assays and pull-down specificity of RNA pull-down
assays were examined. (A) The immunoprecipitated YTHDC1, YTHDC2, YTHDF1,
YTHDF2, YTHDF3 and HNRNPC were detected by Western blotting. (B) The abundance
of circABHD3, ABHD3 mRNA and GAPDH mRNA pulled down by the circABHD3 probe
was examined by qRT-PCR (n = 3). ***P < 0.001.
(TIF)
S3 Fig. ABHD3 mRNA was not enriched by an YTHDF2 antibody. The enrichment of
ABHD3 mRNA by an YTHDF2 antibody was determined with qRT-PCR and electrophoresis
(n = 3).
(TIF)
S4 Fig. Depletion of circABHD3 alleviated liver fibrosis in BDL mice. Wildtype and
circABHD3 KO mice were induced for hepatic fibrosis with BDL and divided into four
groups: Sham-WT, Sham-circABHD3-KO, BDL-WT and BDL-circABHD3-KO. Scale bar,
100 µm. (A) Liver injury and fibrosis were evaluated by H&E, Masson’s trichrome and Sirius
Red staining and α-SMA was detected by IHC staining. (B and C) Serum ALT and AST were
determined by ELISA (n = 6). (D) HYP concentration in the livers was determined (n = 6).
(E) IHC staining of E-cadherin and N-cadherin in the livers. Scale bar, 100 µm or 20 µm.
*P < 0.05, **P < 0.01 and ***P < 0.001.
(TIF)
S1 Table. Numerical values supporting each graph.
(XLSX)
Author contributions
Conceptualization: Limin Chen.
Data curation: Kangkang Fu.
Formal analysis: Haoye Zhang.
Funding acquisition: Zhenguo Liu.
Investigation: Limin Chen.
Methodology: Hui Yang.
Project administration: Kangkang Fu, Yu Yan.
Resources: Juan Wang.
CCl4 + circABHD3-KO + shYPEL3. YPEL3-silencing lentiviral particles were intravenously injected. (A) Liver injury and fibrosis were evaluated by H&E, Masson’s
trichrome and Sirius Red staining and α-SMA was detected by IHC staining. Scale bar, 100 µm. (B and C) Serum ALT and AST were determined by ELISA (n = 6).
(D) HYP concentration in the livers was determined (n = 6). (E) Protein levels of YPEL3, GSK-3β, α-SMA, COL1A1, total and phosphorylated β-catenin in the
livers were examined with Western blotting (n = 6). GAPDH was a loading control for normalization. (F) IHC staining of β-catenin in the livers. Scale bar, 100 µm
or 50 µm. **P < 0.01 and ***P < 0.001.
https://doi.org/10.1371/journal.pgen.1011622.g008
PLOS Genetics | https://doi.org/10.1371/journal.pgen.1011622 March 18, 2025 25 / 29
PLOS GeneticS CircABHD3 exacerbates hepatic brosis via YPEL3-mediated β-catenin signaling
Fig 9. Depletion of circABHD3 inhibited CCl4-induced EMT and mitochondrial impairment in mice. (A) Western
blot analysis of Snail, E-cadherin, N-cadherin, and Vimentin in the livers (n = 6). (B) IHC staining of N- and E-cadherin in
PLOS Genetics | https://doi.org/10.1371/journal.pgen.1011622 March 18, 2025 26 / 29
PLOS GeneticS CircABHD3 exacerbates hepatic brosis via YPEL3-mediated β-catenin signaling
Supervision: Juan Wang.
Validation: Haoye Zhang.
Visualization: Yu Yan.
Writing – original draft: Hui Yang.
Writing – review & editing: Zhenguo Liu.
References
1. Friedman SL. Liver brosis -- from bench to bedside. J Hepatol. 2003;38 Suppl 1:S38-53. https://doi.
org/10.1016/s0168-8278(02)00429-4 PMID: 12591185
2. Tan Z, Sun H, Xue T, Gan C, Liu H, Xie Y, et al. Liver brosis: therapeutic targets and advances in
drug therapy. Front Cell Dev Biol. 2021;9:730176. https://doi.org/10.3389/fcell.2021.730176 PMID:
34621747
3. Larue L, Bellacosa A. Epithelial-mesenchymal transition in development and cancer: role of phos-
phatidylinositol 3’ kinase/AKT pathways. Oncogene. 2005;24(50):7443–54. https://doi.org/10.1038/
sj.onc.1209091 PMID: 16288291
4. Chen Y, Fan Y, Guo D-Y, Xu B, Shi X-Y, Li J-T, et al. Study on the relationship between hepatic brosis
and epithelial-mesenchymal transition in intrahepatic cells. Biomed Pharmacother. 2020;129:110413.
https://doi.org/10.1016/j.biopha.2020.110413 PMID: 32570119
5. Klingberg F, Hinz B, White ES. The myobroblast matrix: implications for tissue repair and brosis. J
Pathol. 2013;229(2):298–309. https://doi.org/10.1002/path.4104 PMID: 22996908
6. Vallée A, Lecarpentier Y. TGF-β in fibrosis by acting as a conductor for contractile properties
of myofibroblasts. Cell Biosci. 2019;9:98. https://doi.org/10.1186/s13578-019-0362-3 PMID:
31827764
7. Zou Y, Li S, Li Z, Song D, Zhang S, Yao Q. MiR-146a attenuates liver brosis by inhibiting transforming
growth factor-β1 mediated epithelial-mesenchymal transition in hepatocytes. Cell Signal. 2019;58:1–8.
https://doi.org/10.1016/j.cellsig.2019.01.012 PMID: 30711634
8. Kim J-Y, An H-J, Kim W-H, Gwon M-G, Gu H, Park Y-Y, et al. Anti-brotic Effects of Synthetic Oligode-
oxynucleotide for TGF-β1 and Smad in an Animal Model of Liver Cirrhosis. Mol Ther Nucleic Acids.
2017;8:250–63. https://doi.org/10.1016/j.omtn.2017.06.022 PMID: 28918026
9. Xue W, Yang L, Chen C, Ashrazadeh M, Tian Y, Sun R. Wnt/β-catenin-driven EMT regulation in
human cancers. Cell Mol Life Sci. 2024;81(1):79. https://doi.org/10.1007/s00018-023-05099-7 PMID:
38334836
10. Gonzalez DM, Medici D. Signaling mechanisms of the epithelial-mesenchymal transition. Sci Signal.
2014;7(344):re8. https://doi.org/10.1126/scisignal.2005189 PMID: 25249658
11. Beljaars L, Daliri S, Dijkhuizen C, Poelstra K, Gosens R. WNT-5A regulates TGF-β-related activities
in liver brosis. Am J Physiol Gastrointest Liver Physiol. 2017;312(3):G219–27. https://doi.org/10.1152/
ajpgi.00160.2016 PMID: 28057611
12. Di Gregorio J, Robuffo I, Spalletta S, Giambuzzi G, De Iuliis V, Toniato E, et al. The epithelial-
to-mesenchymal transition as a possible therapeutic target in brotic disorders. Front Cell Dev Biol.
2020;8:607483. https://doi.org/10.3389/fcell.2020.607483 PMID: 33409282
13. Ge W-S, Wang Y-J, Wu J-X, Fan J-G, Chen Y-W, Zhu L. β-catenin is overexpressed in hepatic bro-
sis and blockage of Wnt/β-catenin signaling inhibits hepatic stellate cell activation. Mol Med Rep.
2014;9(6):2145–51. https://doi.org/10.3892/mmr.2014.2099 PMID: 24691643
14. Zheng H, Yang Z, Xin Z, Yang Y, Yu Y, Cui J, et al. Glycogen synthase kinase-3β: a promising
candidate in the ght against brosis. Theranostics. 2020;10(25):11737–53. https://doi.org/10.7150/
thno.47717 PMID: 33052244
15. Zhang C, Su L, Huang L, Song Z-Y. GSK3β inhibits epithelial-mesenchymal transition via the
Wnt/β-catenin and PI3K/Akt pathways. Int J Ophthalmol. 2018;11(7):1120–8. https://doi.org/10.18240/
ijo.2018.07.08 PMID: 30046527
the livers. Scale bar, 50 µm or 20 µm. (C) Serum 8-OHdG was determined by ELISA. (D) Relative mRNA levels of Drp1,
Fis1, OPA1 and Mfn1 were analyzed by qRT-PCR (n = 6). (E) Mitochondrial morphology and fission were determined with
TEM. Scale bar, 500 nm. *P < 0.05, **P < 0.01 and ***P < 0.001.
https://doi.org/10.1371/journal.pgen.1011622.g009
PLOS Genetics | https://doi.org/10.1371/journal.pgen.1011622 March 18, 2025 27 / 29
PLOS GeneticS CircABHD3 exacerbates hepatic brosis via YPEL3-mediated β-catenin signaling
16. Liu Z, Zhou S, Zhang Y, Zhao M. Rat bone marrow mesenchymal stem cells (BMSCs) inhibit liver
brosis by activating GSK3β and inhibiting the Wnt3a/β-catenin pathway. Infect Agent Cancer.
2022;17(1):17. https://doi.org/10.1186/s13027-022-00432-4 PMID: 35440002
1 7. Zhang J, Wen X, Ren X-Y, Li Y-Q, Tang X-R, Wang Y-Q, et al. YPEL3 suppresses epithelial-
mesenchymal transition and metastasis of nasopharyngeal carcinoma cells through the Wnt/
β-catenin signaling pathway. J Exp Clin Cancer Res. 2016;35(1):109. https://doi.org/10.1186/s13046-
016-0384-1 PMID: 27400785
18. Liu J, Qiu R, Liu R, Song P, Lin P, Chen H, et al. YPEL3 Negatively Regulates Endometrial Function
via the Wnt/beta-Catenin Pathways during Early Pregnancy in Goats. Animals (Basel) 2022;12(21).
19. Maity A, Das B. N6-methyladenosine modication in mRNA: machinery, function and implications
for health and diseases. FEBS J. 2016;283(9):1607–30. https://doi.org/10.1111/febs.13614 PMID:
26645578
20. Zhou Y, Lv X, Qu H, Zhao K, Fu L, Zhu L, et al. Differential expression of circular RNAs in hepatic
tissue in a model of liver brosis and functional analysis of their target genes. Hepatol Res.
2019;49(3):324–34. https://doi.org/10.1111/hepr.13284 PMID: 30379383
2 1. Chen X, Li H-D, Bu F-T, Li X-F, Chen Y, Zhu S, et al. Circular RNA circFBXW4 suppresses hepatic
brosis via targeting the miR-18b-3p/FBXW7 axis. Theranostics. 2020;10(11):4851–70. https://doi.
org/10.7150/thno.42423 PMID: 32308754
22. Bu F-T, Zhu Y, Chen X, Wang A, Zhang Y-F, You H-M, et al. Circular RNA circPSD3 alleviates hepatic
brogenesis by regulating the miR-92b-3p/Smad7 axis. Mol Ther Nucleic Acids. 2021;23:847–62.
https://doi.org/10.1016/j.omtn.2021.01.007 PMID: 33614234
23. Sun Y-L, Bai T, Zhou L, Zhu R-T, Wang W-J, Liang R-P, et al. SOD3 deciency induces liver brosis
by promoting hepatic stellate cell activation and epithelial-mesenchymal transition. J Cell Physiol.
2021;236(6):4313–29. https://doi.org/10.1002/jcp.30174 PMID: 33230845
24. Koo Y, Han W, Keum B-R, Lutz L, Yun SH, Kim G-H, et al. RNF2 regulates Wnt/ß-catenin signaling
via TCF7L1 destabilization. Sci Rep. 2023;13(1):19750. https://doi.org/10.1038/s41598-023-47111-x
PMID: 37957244
25. Zhang K, Zhang M, Yao Q, Han X, Zhao Y, Zheng L, et al. The hepatocyte-specically expressed
lnc-HSER alleviates hepatic brosis by inhibiting hepatocyte apoptosis and epithelial-mesenchymal
transition. Theranostics. 2019;9(25):7566–82. https://doi.org/10.7150/thno.36942 PMID: 31695787
26. Cho I, Koo B-N, Kam EH, Lee SK, Oh H, Kim SY. Bile duct ligation of C57BL/6 mice as a model
of hepatic encephalopathy. Anesth Pain Med (Seoul). 2020;15(1):19–27. https://doi.org/10.17085/
apm.2020.15.1.19 PMID: 33329785
2 7. Claeys W, Van Hoecke L, Geerts A, Van Vlierberghe H, Lefere S, Van Imschoot G, et al. A
mouse model of hepatic encephalopathy: bile duct ligation induces brain ammonia overload,
glial cell activation and neuroinammation. Sci. Rep. 2022;12(1):17558. https://doi.org/10.1038/
s41598-022-22045-5
28. Zhang L, Zhang Y, Chang X, Zhang X. Imbalance in mitochondrial dynamics induced by low PGC-1α
expression contributes to hepatocyte EMT and liver brosis. Cell Death Dis. 2020;11(4):226. https://
doi.org/10.1038/s41419-020-2429-9 PMID: 32269221
29. Yang YR, Hu S, Bu FT, Li H, Huang C, Meng XM, et al. Circular RNA CREBBP suppresses hepatic
brosis via targeting the hsa-miR-1291/LEFTY2 Axis. Front. Pharmacol. 2021, 12:741151.
30. Myint M, Oppedisano F, De Giorgi V, Kim B-M, Marincola FM, Alter HJ, et al. Inammatory signaling
in NASH driven by hepatocyte mitochondrial dysfunctions. J Transl Med. 2023;21(1):757. https://doi.
org/10.1186/s12967-023-04627-0 PMID: 37884933
3 1. Meng Y, Zhao T, Zhang Z, Zhang D. The role of hepatic microenvironment in hepatic brosis devel-
opment. Ann Med. 2022;54(1):2830–44. https://doi.org/10.1080/07853890.2022.2132418 PMID:
36399108
32. Sharma S, Le Guillou D, Chen J. Cellular stress in the pathogenesis of nonalcoholic steatohepatitis
and liver brosis. Nature Reviews Gastroenterology & Hepatology. 2023;20(10):662–78.
33. Wei J, Li M, Xue C, Chen S, Zheng L, Deng H, et al. Understanding the roles and regulation pat-
terns of circRNA on its host gene in tumorigenesis and tumor progression. J Exp Clin Cancer Res.
2023;42(1):86. https://doi.org/10.1186/s13046-023-02657-6 PMID: 37060016
34. Fontemaggi G, Turco C, Esposito G, Di Agostino S. New Molecular Mechanisms and Clinical Impact
of circRNAs in Human Cancer. Cancers (Basel). 2021;13(13):3154. https://doi.org/10.3390/can-
cers13133154 PMID: 34202482
35. Li Q, Yang G, Ren B, Liu X, Tang LQ, Shi Q, et al. ZC3H14 facilitates backsplicing by binding to
exon-intron boundary and 3’ UTR. Mol Cell 2024.
PLOS Genetics | https://doi.org/10.1371/journal.pgen.1011622 March 18, 2025 28 / 29
PLOS GeneticS CircABHD3 exacerbates hepatic brosis via YPEL3-mediated β-catenin signaling
36. Kelley KD, Miller KR, Todd A, Kelley AR, Tuttle R, Berberich SJ. YPEL3, a p53-regulated gene that
induces cellular senescence. Cancer Res. 2010;70(9):3566–75. https://doi.org/10.1158/0008-5472.
CAN-09-3219 PMID: 20388804
3 7. Zhou M, Liu W, Zhang J, Sun N. RNA m6A modication in immunocytes and DNA Repair: the bio-
logical functions and prospects in clinical application. Front Cell Dev Biol. 2021;9:794754. https://doi.
org/10.3389/fcell.2021.794754 PMID: 34988083
38. Dhar D, Baglieri J, Kisseleva T, Brenner DA. Mechanisms of liver brosis and its role in liver cancer.
Exp Biol Med (Maywood). 2020;245(2):96–108. https://doi.org/10.1177/1535370219898141 PMID:
31924111
39. Asrani SK, Devarbhavi H, Eaton J, Kamath PS. Burden of liver diseases in the world. J. Hepatol.
2019;70(1):151–71.
40. Bataller R, Brenner DA. Liver brosis. J Clin Invest. 2005;115(2):209–18. https://doi.org/10.1172/
JCI24282 PMID: 15690074
4 1. Murphy FR, Issa R, Zhou X, Ratnarajah S, Nagase H, Arthur MJP, et al. Inhibition of apoptosis
of activated hepatic stellate cells by tissue inhibitor of metalloproteinase-1 is mediated via effects
on matrix metalloproteinase inhibition: implications for reversibility of liver brosis. J Biol Chem.
2002;277(13):11069–76. https://doi.org/10.1074/jbc.M111490200 PMID: 11796725
42. Zeisberg M, Yang C, Martino M, Duncan MB, Rieder F, Tanjore H, et al. Fibroblasts derive
from hepatocytes in liver brosis via epithelial to mesenchymal transition. J Biol Chem.
2007;282(32):23337–47. https://doi.org/10.1074/jbc.M700194200 PMID: 17562716
43. Taura K, Iwaisako K, Hatano E, Uemoto S. Controversies over the epithelial-to-mesenchymal transi-
tion in liver brosis. J Clin Med. 2016;5(1):9. https://doi.org/10.3390/jcm5010009 PMID: 26784242
44. Taura K, Miura K, Iwaisako K, Osterreicher CH, Kodama Y, Penz-Osterreicher M, et al. Hepato-
cytes do not undergo epithelial-mesenchymal transition in liver brosis in mice. Hepatology.
2010;51(3):1027–36. https://doi.org/10.1002/hep.23368 PMID: 20052656
45. Chu AS, Diaz R, Hui JJ, Yanger K, Zong Y, Alpini G, et al. Lineage tracing demonstrates no evidence
of cholangiocyte epithelial-to-mesenchymal transition in murine models of hepatic brosis. Hepatol-
ogy 2011;53(5):1685–95.
46. Zhao W, Cui Y, Liu L, Qi X, Liu J, Ma S, et al. Splicing factor derived circular RNA circUHRF1
accelerates oral squamous cell carcinoma tumorigenesis via feedback loop. Cell Death Differ.
2020;27(3):919–33. https://doi.org/10.1038/s41418-019-0423-5 PMID: 31570856
4 7. Xu G, Zhang P, Liang H, Xu Y, Shen J, Wang W, et al. Circular RNA hsa_circ_0003288 induces EMT
and invasion by regulating hsa_circ_0003288/miR-145/PD-L1 axis in hepatocellular carcinoma.
Cancer Cell Int. 2021;21(1):212. https://doi.org/10.1186/s12935-021-01902-2 PMID: 33858418
48. Zeng X, Yuan X, Cai Q, Tang C, Gao J. Circular RNA as an epigenetic regulator in chronic liver dis-
eases. Cells. 2021;10(8):1945. https://doi.org/10.3390/cells10081945 PMID: 34440714
49. Wang W, Dong R, Guo Y, He J, Shao C, Yi P, et al. CircMTO1 inhibits liver brosis via regulation
of miR-17-5p and Smad7. J Cell Mol Med. 2019;23(8):5486–96. https://doi.org/10.1111/jcmm.14432
PMID: 31148365
50. Zhu S, Chen X, Wang J, Xu J, Wang A, Li J, et al. Circular RNA circUbe2k promotes hepatic brosis
via sponging miR-149-5p/TGF-beta2 axis. FASEB J: 2021;35(6):e21622.
5 1. Wang G, Tong J, Li Y, Qiu X, Chen A, Chang C, et al. Overview of CircRNAs roles and mechanisms in
liver brosis. Biomolecules. 2023;13(6):940. https://doi.org/10.3390/biom13060940 PMID: 37371520
52. Memczak S, Papavasileiou P, Peters O, Rajewsky N. Identication and characterization of circular
RNAs as a new class of putative biomarkers in human blood. PLoS One. 2015;10(10):e0141214.
https://doi.org/10.1371/journal.pone.0141214 PMID: 26485708
53. Wang X, Lu Z, Gomez A, Hon GC, Yue Y, Han D, et al. N6-methyladenosine-dependent regulation of
messenger RNA stability. Nature. 2014;505(7481):117–20. https://doi.org/10.1038/nature12730 PMID:
24284625
54. Du H, Zhao Y, He J, Zhang Y, Xi H, Liu M, et al. YTHDF2 destabilizes m(6)A-containing RNA through
direct recruitment of the CCR4-NOT deadenylase complex. Nat Commun. 2016;7:12626. https://doi.
org/10.1038/ncomms12626 PMID: 27558897
55. Heck AM, Russo J, Wilusz J, Nishimura EO, Wilusz CJ. YTHDF2 destabilizes m6A-modied
neural-specic RNAs to restrain differentiation in induced pluripotent stem cells. RNA.
2020;26(6):739–55. https://doi.org/10.1261/rna.073502.119 PMID: 32169943
56. Park OH, Ha H, Lee Y, Boo SH, Kwon DH, Song HK, Kim YK. Endoribonucleolytic cleavage of
m(6)A-containing RNAs by RNase P/MRP complex. Mol Cell 2019;74(3):494–507 e498.
PLOS Genetics | https://doi.org/10.1371/journal.pgen.1011622 March 18, 2025 29 / 29
PLOS GeneticS CircABHD3 exacerbates hepatic brosis via YPEL3-mediated β-catenin signaling
5 7. Boo SH, Ha H, Lee Y, Shin M-K, Lee S, Kim YK. UPF1 promotes rapid degradation of m6A-containing
RNAs. Cell Rep. 2022;39(8):110861. https://doi.org/10.1016/j.celrep.2022.110861 PMID: 35613594
58. Pan X, Bi Y, Cheng M, Qian Z, Wang L, You H, et al. METTL3 facilitates hepatic brosis pro-
gression via m6A-YTHDF2 dependent silencing of GPR161. bioRxiv. 2021. https://doi.
org/10.1101/2021.12.15.472749
59. Wu M, Chen G, Liao X, Xiao L, Zheng J. YTHDF2 interference suppresses the EMT of cervical can-
cer cells and enhances cisplatin chemosensitivity by regulating AXIN1. Drug Dev. Res. 2022.
60. Xu P, Hu K, Zhang P, Sun Z-G, Zhang N. Hypoxia-mediated YTHDF2 overexpression promotes
lung squamous cell carcinoma progression by activation of the mTOR/AKT axis. Cancer Cell Int.
2022;22(1):13. https://doi.org/10.1186/s12935-021-02368-y PMID: 34996459
6 1. Zhang E, Yang Y, Chen S, Peng C, Lavin MF, Yeo AJ, et al. Bone marrow mesenchymal stromal cells
attenuate silica-induced pulmonary brosis potentially by attenuating Wnt/β-catenin signaling in rats.
Stem Cell Res Ther. 2018;9(1):311. https://doi.org/10.1186/s13287-018-1045-4 PMID: 30428918
62. Hu L, Ding M, He W. Emerging therapeutic strategies for attenuating tubular EMT and kidney brosis
by targeting Wnt/β-catenin signaling. Front Pharmacol. 2022;12:830340. https://doi.org/10.3389/
fphar.2021.830340 PMID: 35082683
63. Skurk C, Maatz H, Rocnik E, Bialik A, Force T, Walsh K. Glycogen-Synthase Kinase3beta/beta-
catenin axis promotes angiogenesis through activation of vascular endothelial growth factor signaling
in endothelial cells. Circ Res. 2005;96(3):308–18. https://doi.org/10.1161/01.RES.0000156273.30274.
f7 PMID: 15662032
64. Tuttle R, Miller KR, Maiorano JN, Termuhlen PM, Gao Y, Berberich SJ. Novel senescence associated
gene, YPEL3, is repressed by estrogen in ER+ mammary tumor cells and required for tamoxifen-
induced cellular senescence. Int J Cancer. 2012;130(10):2291–9. https://doi.org/10.1002/ijc.26239
PMID: 21671470
